OMNIAB, INC. Increase (Decrease) in Contract with Customer, Liability
OMNIAB, INC. (OABI) reported Increase (Decrease) in Contract with Customer, Liability of -$978.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- OMNIAB, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$800.00K, a 40100.00% decline year-over-year.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$178.00K.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$589.00K, a 1006.15% decline year-over-year.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $451.00K.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$1.60M.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$5.99M.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$5.35M.
- OMNIAB, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$9.49M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$978.00K 10-Q · filed 2026-08-06 | -$1.57M derived: sum of 3 quarters · filed 2026-08-06 | -$1.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$178.00K 10-Q · filed 2026-05-07 | -$767.00K derived: sum of 2 quarters · filed 2026-05-07 | -$316.00K derived: sum of 3 quarters · filed 2026-05-07 | -$314.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$138.00K derived: sum of 2 quarters · filed 2026-03-04 | -$136.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.60M 10-K · filed 2026-03-04 |
| 2025-09-30 | $451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $453.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.01M 10-Q · filed 2025-11-04 | -$946.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.46M 10-Q · filed 2026-08-06 | -$1.40M derived: sum of 3 quarters · filed 2026-08-06 | -$2.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.46M 10-Q · filed 2026-05-07 | -$1.40M derived: sum of 2 quarters · filed 2026-05-07 | -$2.25M derived: sum of 3 quarters · filed 2026-05-07 | -$5.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$790.00K derived: sum of 2 quarters · filed 2026-03-04 | -$3.74M derived: sum of 3 quarters · filed 2026-03-04 | -$5.99M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$855.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$3.80M derived: sum of 2 quarters · filed 2025-11-04 | -$6.05M 10-Q · filed 2025-11-04 | -$7.37M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$2.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$5.20M 10-Q · filed 2025-08-06 | -$6.51M derived: sum of 3 quarters · filed 2025-08-06 | -$7.40M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$2.25M 10-Q · filed 2025-05-08 | -$3.56M derived: sum of 2 quarters · filed 2025-05-08 | -$4.45M derived: sum of 3 quarters · filed 2025-05-08 | -$4.61M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$2.20M derived: sum of 2 quarters · filed 2025-03-18 | -$2.36M derived: sum of 3 quarters · filed 2025-03-18 | -$5.35M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$888.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.05M derived: sum of 2 quarters · filed 2024-11-12 | -$4.04M 10-Q · filed 2024-11-12 | -$7.14M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.15M 10-Q · filed 2024-08-08 | -$6.25M derived: sum of 3 quarters · filed 2024-08-08 | -$5.96M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$2.99M 10-Q · filed 2024-05-09 | -$6.09M derived: sum of 2 quarters · filed 2024-05-09 | -$5.80M derived: sum of 3 quarters · filed 2024-05-09 | -$8.65M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$2.82M derived: sum of 2 quarters · filed 2024-03-25 | -$5.67M derived: sum of 3 quarters · filed 2024-03-25 | -$9.49M 10-K · filed 2024-03-25 |
| 2022-09-30 | $289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.56M derived: sum of 2 quarters · filed 2023-11-09 | -$6.38M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$6.67M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$3.82M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$6.72M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |